Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | DRD3 | P35462 | 4/20 | 0.56 |
| ▸ | DRD1 | P21728 | 3/20 | 0.56 |
| ▸ | DRD5 | P21918 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20835002 | 0.93 | HTR1A (0.58) | LMNAHTR1ADRD2HTR2ADRD3 | |
| SCHEMBL26493117 | 0.93 | HTR1A (0.58) | LMNAHTR1ADRD2HTR2ADRD3 | |
| SCHEMBL9535253 | 0.93 | HTR1A (0.58) | LMNAHTR1ADRD2HTR2ADRD3 | |
| SCHEMBL3910170 | 0.89 | LMNA (0.57) | LMNAMAPTHTR1ADRD2HTR2A | |
| SCHEMBL26108581 | 0.87 | HTR1A (0.65) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL26492991 | 0.87 | HTR1A (0.65) | HTR1ADRD2HTR2ADRD3DRD1 | |
| Pyrazole SCHEMBL9739326 | 0.86 | HRH3 (0.48) | LMNATP53MAPTHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL26108377 | 0.85 | DRD2 (0.63) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL7656340 | 0.84 | CYP2D6 (0.59) | HTR1ADRD2HTR2ADRD3DRD1 | |
| SCHEMBL1254644 | 0.84 | HTR1A (0.57) | HTR1ADRD2HTR2ADRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012050884-A2 | CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-04-19 | — | — | WO | claimed |
| EP-3411040-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | President and Fellows of Harvard College (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-3332645-A1 | USE OF SUBSTITUTED PYRIMIDINE DIONES OR THEIR SALTS AS AGENTS TO COMBAT ABIOTIC PLANT STRESS | Bayer Cropscience AG (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-20170258819-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| WO-2017136480-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-10 | — | — | WO | disclosed |
| US-9549983-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2646107-A2 | AGENT DELIVERY SYSTEMS FOR SELECTIVE NEUROMODULATION | Spinal Modulation Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012174537-A2 | SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012075337-A2 | DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY | SPINAL MODULATION, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | UNIVERSITA DI PISA, 40% (IT) | 2009-04-09 | — | — | US | disclosed |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | UNIVERSITA DI PISA, 40% (IT) | 2009-04-09 | — | — | US | disclosed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258819-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, TNF | LMNA 3286/4885TP53 2842/4885MAPT 3573/4885 |
| US-20090093493-A1 | 1-PHENYLALCOXY-2-BETA-PHENYLETHYL DERIVATIVES AS P-GLYCOPROTEIN (P-GP) INHIBITORS USEFUL IN DRUG RESISTANCE EVENTS | ABCB1, ABCC1, ABCC2 | LMNA 2605/4885TP53 336/4885MAPT 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.